Used in the treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is effective due to its ability to inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. Its once-daily dosing and activity against resistant strains make it a valuable option in outpatient and hospital settings. It also shows potential for treating other Gram-positive infections with lower risk of developing resistance compared to older antibiotics.